Latest Breaking News On - Josephine belluardo - Page 7 : comparemela.com
Share this article
HOLON, Israel, March 9, 2021 /PRNewswire/
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a review article titled Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis reviewing the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy. The peer-reviewed article, published in
Cancer Discovery, a journal of the American Association for Cancer Research, was co-authored by Drew Pardoll, M.D., Ph.D., Professor of Oncology, Johns Hopkins University and Chairman of Compugen s Scientific Advisory Board.
Article highlights include:
Detailed overview of the DNAM-1 axis including axis checkpoint molecules: DNAM-1, TIGIT, PVRIG and CD96, along with their ligands PVR and PVRL2
United-statesIsraelTel-avivAmericanElana-holzmanJosephine-belluardoBob-yedidJohns-hopkins-universityLifesci-advisorsCompugen-ltdCorporate-communications-compugen-ltdCompugen